Spreadsheet: 1f658641-a200-4037-a973-ec869bd8f13a
Sheet: Tb45

 | Estimated Vaccination Coverage^ with Individual Vaccines and Vaccination Series Among Children 19-35 Months of Age by Race/Ethnicity* -- US, National Immunization Survey, Q1/2011-Q4/2011†
[NAME] | US National | White only,                        non-Hispanic | Black only,                         non-Hispanic | Hispanic | American Indian or [NAME] only, non-Hispanic | Asian only, non-Hispanic | Native Hawaiian or other Pacific Islander only, non-Hispanic | Multiple Race, non-Hispanic
3+DTaP¥ | 95.5±0.5 | 95.5±0.7 | 94.7±1.5 | 95.6±1.0 | 89.6±7.3 | 97.9±1.3 | 99.3±1.3 | 95.3±2.7
4+DTaP‡ | 84.6±1.0 | 85.0±1.3 | 81.3±2.9 | 84.1±2.2 | 72.7±9.5 | 92.0±2.5 | 93.0±5.7 | 87.1±3.7
3+Polio§ | 93.9±0.6 | 93.9±0.8 | 93.9±1.6 | 93.8±1.4 | 88.1±7.4 | 96.5±1.7 | 96.6±5.4 | 93.5±3.0
1+MMRll | 91.6±0.8 | 91.1±0.9 | 90.8±2.2 | 92.4±1.8 | 94.8±4.8 | 93.9±2.8 | 98.7±1.7 | 91.1±3.6
3+Hib¶ | 94.0±0.6 | 94.1±0.8 | 93.0±1.8 | 94.4±1.2 | 85.8±7.8 | 94.6±2.3 | 98.9±1.5 | 94.4±2.8
Hib-PS** | 94.2±0.6 | 94.2±0.8 | 93.0±1.8 | 94.5±1.2 | 91.7±6.6 | 94.6±2.3 | 98.9±1.5 | 94.4±2.8
Hib-FS†† | 80.4±1.1 | 81.0±1.4 | 74.6±3.3 | 81.6±2.2 | 73.7±9.6 | 83.5±4.7 | NA | 82.0±4.6
3+HepB‡‡ | 91.1±0.7 | 90.3±1.0 | 92.1±1.8 | 91.5±1.6 | 92.6±6.5 | 95.5±2.0 | 91.1±9.5 | 90.7±3.7
[NAME] dose§§ | 68.6±1.3 | 66.0±1.6 | 73.4±3.4 | 70.8±2.9 | 83.6±5.9 | 69.0±6.5 | NA | 65.2±6.0
1+Varllll | 90.8±0.7 | 89.6±1.0 | 91.2±2.3 | 92.0±1.5 | 90.1±7.2 | 93.5±2.5 | 99.0±1.5 | 91.9±3.2
3+PCV¶¶ | 93.6±0.6 | 93.4±0.8 | 93.4±1.7 | 94.3±1.2 | 85.5±8.7 | 92.5±2.9 | 99.3±1.3 | 94.4±2.8
4+PCV*** | 84.4±1.0 | 85.3±1.2 | 81.3±2.8 | 84.6±2.1 | 75.3±9.3 | 84.9±4.7 | 93.1±6.5 | 84.0±4.2
1+HepA††† | 81.2±1.0 | 77.0±1.3 | 83.1±2.6 | 86.7±1.9 | 81.7±8.2 | 87.1±5.6 | NA | 79.5±5.2
2+HepA††† | 52.2±1.4 | 50.0±1.6 | 50.9±3.7 | 56.3±3.2 | NA | 56.9±7.1 | NA | 50.2±6.6
Rotavirus‡‡‡ | 67.3±1.3 | 68.3±1.6 | 62.5±3.5 | 68.3±2.9 | 57.7±9.5 | 66.9±6.1 | NA | 67.8±5.7
4:3:1§§§ | 82.6±1.0 | 82.6±1.3 | 79.6±3.0 | 82.6±2.3 | 72.7±9.5 | 90.5±2.9 | 90.0±7.6 | 85.4±4.0
4:3:1:3llllll | 81.9±1.0 | 82.0±1.3 | 78.9±3.0 | 81.9±2.4 | 71.9±9.5 | 88.2±3.4 | 89.8±7.7 | 84.7±4.1
(4:3:1:2*)¶¶¶ | 81.9±1.0 | 82.0±1.3 | 78.9±3.0 | 81.9±2.4 | 72.4±9.5 | 88.2±3.4 | 89.8±7.7 | 84.7±4.1
(4:3:1:3*)**** | 75.4±1.2 | 76.0±1.5 | 69.5±3.5 | 76.1±2.6 | 69.1±9.5 | 80.9±5.0 | NA | 78.0±4.9
4:3:1:3:3:1€ | 77.0±1.1 | 76.8±1.4 | 74.6±3.3 | 77.1±2.5 | 71.4±9.5 | 83.2±4.1 | NA | 78.9±4.8
4:3:1:-:3:1ς | 77.6±1.1 | 77.3±1.4 | 75.3±3.3 | 77.9±2.5 | 72.2±9.5 | 85.4±3.8 | NA | 79.6±4.7
4:3:1:2*:3:1€€ | 77.0±1.1 | 76.9±1.4 | 74.6±3.3 | 77.1±2.5 | 71.9±9.5 | 83.2±4.1 | NA | 78.9±4.8
4:3:1:3*:3:1ςς | 71.0±1.2 | 71.2±1.6 | 66.0±3.6 | 71.7±2.7 | 68.6±9.5 | 77.2±5.3 | NA | 73.2±5.3
4:3:1:3:3:1:4€€€ | 73.3±1.2 | 73.5±1.5 | 70.1±3.4 | 73.8±2.7 | 68.7±9.5 | 76.4±5.4 | NA | 74.3±5.1
4:3:1:-:3:1:4ςςς | 73.6±1.2 | 73.7±1.5 | 70.7±3.4 | 74.4±2.6 | 69.5±9.5 | 76.6±5.4 | NA | 74.5±5.1
4:3:1:2*:3:1:4€€€€ | 73.3±1.2 | 73.5±1.5 | 70.1±3.4 | 73.8±2.7 | 69.2±9.5 | 76.4±5.4 | NA | 74.3±5.1
4:3:1:3*:3:1:4ςςςς | 68.5±1.3 | 68.8±1.6 | 63.7±3.7 | 69.5±2.8 | 65.9±9.5 | 70.8±6.1 | NA | 70.9±5.5
 | ^ Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588 or (CI half width) >10. Estimates presented as point estimate (%) ± 95% Confidence Interval.
 | * Self-reported by respondent. Children of Hispanic ethnicity may be of any race.
 | † Children in the Q1/2011-Q4/2011 National Immunization Survey were born from January 2008 through May 2010.
 | ¥  3 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT).
 | ‡ 4 or more doses of DTaP.
 | § 3 or more doses of any poliovirus vaccine.
 | ll 1 or more doses of measles-mumps-rubella vaccine.
 | ¶ 3 or more doses of Haemophilus influenzae type b (Hib) vaccine.
 | ** Primary series Hib: ≥2 or ≥3 doses of Haemophilus influenzae type b (Hib), depending on brand type.
 | †† Full series Hib: ≥3 or ≥4 doses of Hib vaccine depending on product type received (includes primary series plus the booster dose).
 | ‡‡ 3 or more doses of hepatitis B vaccine.
 | §§ 1 or more doses of hepatitis B vaccine administered between birth and age 3 days.
 | llll 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness.
 | ¶¶ 3 or more doses of pneumococcal conjugate vaccine (PCV).
 | *** 4 or more doses of PCV.
 | # 1 or more doses of hepatitis A vaccine
 | ††† 2 or more doses of hepatitis A vaccine.
 | ‡‡‡ ≥2 or ≥3 doses of [NAME] vaccine, depending on product type received (≥2 doses for Rotarix® [RVI] or ≥3 doses for RotaTeq® [RV5]).
 | §§§ 4 or more doses of DTaP, 3 or more doses of poliovirus vaccine, and 1 or more doses of any MMR vaccine.
 | llllll 4:3:1 plus 3 or more doses of Hib vaccine of any type.
 | ¶¶¶ 4:3:1 plus the primary series Hib.
 | ****  4:3:1 plus the full series Hib.
 | € 4:3:1 plus 3 or more doses of Hib vaccine of any type, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ς 4:3:1 plus 3 or more doses of HepB vaccine and 1 or more doses of varicella vaccine. Hib vaccine is excluded.
 | €€ 4:3:1 plus primary series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ςς 4:3:1 plus full series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | €€€ 4:3:1 plus ≥3 doses of Hib vaccine of any type, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςς  4:3:1 plus 3 or more doses of HepB vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.  Hib vaccine is excluded.
 | €€€€ 4:3:1 plus primary series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςςς 4:3:1 plus full series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.